China Resources Double-Crane PharmaceuticalLtd 관리

관리 기준 확인 0/4

China Resources Double-Crane PharmaceuticalLtd CEO는 Wenchao Lu, Jul2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 CN¥ 5.47M 가치에 해당하는 회사 주식의 0.024% 직접 소유합니다. 5.47M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 2.9 년입니다.

주요 정보

Wenchao Lu

최고 경영자

CN¥2.3m

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.02%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO

Wenchao Lu (47 yo)

less than a year

테뉴어

CN¥2,319,500

보상

Mr. Wenchao Lu is Chairman of the board of China Resources Double-Crane Pharmaceutical Co. Ltd. from September 21, 2023 and serves as its Acting President since July 2024. Mr. Lu was President of China Res...

리더십 팀

이름	위치	테뉴어	보상	소유권
Wenchao Lu	Chairman of the Board & Acting President	less than a year	CN¥2.32m	0.024% CN¥ 5.5m
Hekai Tan	VP & Company Secretary	no data	CN¥1.11m	0.014% CN¥ 3.2m
Ziqin Liu	Vice President	3.8yrs	CN¥1.60m	0.018% CN¥ 4.1m
Chao Man	Vice President	3.8yrs	CN¥1.80m	0.025% CN¥ 5.7m
Donghan Yao	Vice President	1.8yrs	CN¥923.00k	데이터 없음
Ju Liu	Chief Financial Officer	less than a year	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 600062 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wenchao Lu	Chairman of the Board & Acting President	2.3yrs	CN¥2.32m	0.024% CN¥ 5.5m
Xiangming Li	Director	3.1yrs	데이터 없음	데이터 없음
Ning Liu	Independent Director	3.3yrs	CN¥150.00k	데이터 없음
Maozhu Sun	Independent Director	3.3yrs	CN¥150.00k	데이터 없음
Na Tang	Chairman of the Supervisory Board	3.3yrs	데이터 없음	데이터 없음
Lili Yan	Employee Supervisor	8.2yrs	데이터 없음	데이터 없음
Zhanfeng Yang	Director	3.3yrs	데이터 없음	데이터 없음
Xiaosong Bai	Director	2.7yrs	데이터 없음	데이터 없음
Shutian Yu	Director	1.9yrs	데이터 없음	데이터 없음
Hui Xu	Director	1.1yrs	데이터 없음	데이터 없음
Guolong Lin	Director	1.1yrs	데이터 없음	데이터 없음
Zhen Chen	Independent Director	less than a year	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 600062 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

China Resources Double-Crane PharmaceuticalLtd 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 3Q 2023)

Investor sentiment improves as stock rises 15%

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥1.30 (vs CN¥1.12 in FY 2022)

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: CN¥1.12 (vs CN¥0.90 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.27 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령